Tyra BiosciencesTYRA +3.07%28 Quick Ratio is 20.49 as of Mar. 2026, which is 38% below its 10-year median of 32.84. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Tyra Biosciences ranks better than 92.87% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Tyra Biosciences's quick ratio for the quarter that ended in Mar. 2026 was 20.49.
Tyra Biosciences has a quick ratio of 20.49. It generally indicates good short-term financial strength.
The historical rank and industry rank for Tyra Biosciences's Quick Ratio or its related term are showing as below:
TYRA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 32.84 Max: 84.09
Current: 20.49
During the past 7 years, Tyra Biosciences's highest Quick Ratio was 84.09. The lowest was 0.02. And the median was 32.84.
TYRA's Quick Ratio is ranked better than 92.87% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs TYRA: 20.49
Tyra Biosciences (NAS:TYRA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tyra Biosciences Quick Ratio Related Terms
Tyra Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Tyra Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tyra Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tyra Biosciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Tyra Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Tyra Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tyra Biosciences (TYRA) has a Quick Ratio of 20.49 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tyra Biosciences and its competitors. This is 38% below median its historical median of 32.84. Over the past decade, Tyra Biosciences' Quick Ratio has ranged from 0.02 to 84.09. According to the industry distribution chart, Tyra Biosciences ranks #101 out of 1416 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Tyra Biosciences' Quick Ratio too high?
Tyra Biosciences' current Quick Ratio of 20.49 is 38% below median its 10-year median of 32.84. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 84.09. The Biotechnology industry median Quick Ratio is 3.60. Tyra Biosciences' value of 20.49 is 469.2% above this industry median. Based on the distribution chart, Tyra Biosciences ranks #101 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Quick Ratio compare to ZLAB and OCUL?
According to the Biotechnology industry distribution chart, Tyra Biosciences ranks #101 out of 1416 companies for Quick Ratio. This places Tyra Biosciences in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Tyra Biosciences' value of 20.49 is 469.2% above this benchmark. Historically, Tyra Biosciences' own Quick Ratio has ranged from 0.02 to 84.09 over the past decade. While the company's 10-year median is 32.84 vs. the industry median of 3.60, Tyra Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tyra Biosciences's current Quick Ratio of 20.49 is 469.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tyra Biosciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tyra Biosciences's current Quick Ratio is 20.49, which is 38% below median its own 10-year median of 32.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Quick Ratio of 20.49. The current Quick Ratio is 20.49, which is 38% below median its 10-year median of 32.84 and 469.2% above the Biotechnology industry median of 3.60. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Quick Ratio is 20.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score
Get the complete analysis for TYRA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYRA has been successfully added to your 
